CCR3 and fatty liver disease: Their findings reveal that the CCL11/CCR3 axis drives macrophage-mediated inflammation and hepatic steatosis, while the genetic ablation of CCL11 or a pharmacological CCR3 blockade significantly attenuates ALD progression [79].